drugset
Drugs / Adenovirus-transfected DC
last change Dec 2024 re-read 9 days ago

Adenovirus-transfected DC

also known as Adenovirus-transfected autologous DC vaccine · DC vaccine

Vaccine

Developed for
renal cell carcinoma · soft tissue sarcoma
Investigated by
Affiliated Hospital to Academy of Military Medical Sciences

Trials 2

today NCT01924156 · Ph 1/2 NCT01898663 · Ph 1/2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01924156 Jul 2013 → Dec 2016 renal cell carcinoma Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT01898663 Jun 2013 → Dec 2024 soft tissue sarcoma Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as adenovirus-transfected DC ClinicalTrials.gov intervention name — accepted as the source's own label NCT01924156 ↗
1

NCT01898663 ↗
Known as Adenovirus-transfected autologous DC vaccine “Adenovirus-transfected autologous DC vaccine plus CIK cells” NCT01898663 ↗
Known as DC vaccine “adenovirus-transfected DC vaccine plus CIK cells” NCT01924156 ↗
Modality Vaccine “DCs vaccine” NCT01898663 ↗